Clin Osteol 2015; 20(3): 123-129

Retrospective study of denosumab treatment in dialysis patientsCase reports

V. Spustová, J. Rosenberger, I. Lajdová, L. Wsolová

Objective: The aim of this retrospective study was to evaluate exp on hemodialysis (CKD 5D) based on available laboratory parameters.

Patients and Methods: The study comprised 33 hemodialysis patients from 18 dialysis centers in Slovakia. Patients received a single dose of denosumab and, on a monthly basis, concentrations of calcium, phosphorus and intact parathyroid hormone (iPTH) were mo­ nitored over a period of six months. The da of p < 0.05 were considered significant.

Results: Serum calcium concentration significantly decreased at one month after denosumab administration, with 15 patients (45 %) having concentrations 1.8 mmol/L. At the same time, there was a significant increase in iPTH concentrations and a decrease in serum phosphorus levels. These changes resulted in treatment modification in each patient. Fifteen patients had baseline iPTH concentra­ tions above 150 pg/mL (suspected mixed or high turnover bone disease; Group I); the other 18 patients had concentrations below 150 pg/mL (suspected adynamic bone disease; Group II). The wing the administration of denosumab varied in the groups.

Conclusion: Treatment with denosumab in patients with CKD 4-5D is currently not evidence-based. Cooperation is necessary between nephrologists and specialists who decide on denosumab treatment. Further research is needed for identification of patients at the hig­ hest risk, finding optimal strategies to minimize serious adverse events and especially histological co

Keywords: chronic kidney disease-mineral and bone disorder (CKD-MBD), denosumab, hypocalcemia, parathy­ roid hormone (PTH), high and low turnover bone disease

Published: December 11, 2015  Show citation